redlight.store

Ex vivo (human) · 2024 · USA (Boston, MA)

Rectifying the impairment of immune thrombocytopenia plasmas through photobiomodulation

Wang · Innov Med · 2024

The protocol this study used

Wavelength
980 nm
Dose
0.03 J/cm²
Sessions
—
Per session
30 sec

What the authors concluded

The current investigation shows that while anti-platelet antibodies and ITP plasmas hinder megakaryocyte differentiation and maturation and impair proplatelet and platelet formation in ex vivo culture of umbilical cord human CD34+ stem cells (cHSCs), low-level laser (LLL) treatment or photobiomodulation (PBM) effectively mitigates these detrimental impacts. PBM reinstated megakaryocyte differenti

Source

Dosimetry extracted by Vladimir Heiskanen in Photobiomodulation (PBM) research - a comprehensive database. Citation resolved against PubMed.